Saturday 17 October 2026
Export ORGS’s income statement to Excel — free account
Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.
0.06
0.06
Infinity
Follow ORGS
Orgenesis Inc. (ORGS) P/E ratio
Orgenesis Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 9.4× (November 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 2.0× | (60.08%) |
| FY2019 | 5.0× | — |
| FY2018 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2024 | 0.0× | — |
| Sep 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| 34 more quarters | Free account |
Against its own ten years
Low 0.0×
High 9.4×
Ten-year median
0.0×
Current reading's percentile
83
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRAW Traws Pharma, Inc. compare | n/m |
| NRSN NeuroSense Therapeutics Ltd. compare | n/m |
| CDIO Cardio Diagnostics Holdings, Inc. compare | n/m |
| ORGS Orgenesis Inc. | n/m |
| CANF Can-Fite Biopharma Ltd compare | n/m |
| BGMS Bio Green Med Solution, Inc. compare | n/m |
| IMNN Imunon, Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)